Welcome to our dedicated page for Tevogen Bio news (Ticker: TVGN), a resource for investors and traders seeking the latest updates and insights on Tevogen Bio stock.
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) is a clinical-stage biotechnology company focused on precision T cell therapies and AI-enabled drug development, and its news flow reflects this dual emphasis on immunotherapy and advanced analytics. Company updates frequently highlight progress on its ExacTcell™ platform, which generates target-specific cytotoxic T lymphocytes for infectious diseases, cancers, and neurological disorders.
Investors and observers following TVGN news can expect coverage of clinical milestones, such as proof-of-concept data for its investigational COVID-19 and Long COVID therapy TVGN 489, expansion of HLA coverage to reach broader patient populations, and preclinical advances in areas like EBV-associated lymphomas, chronic hepatitis B, and HPV-related cancers. Tevogen also reports on developments in Tevogen.AI and its PredicTcell™ model, including patent activity and progress in predictive technologies for immunologically active peptides.
Financial and corporate news for Tevogen often centers on capital efficiency, non-GAAP operating metrics, and commentary on how GAAP accounting reflects high-growth biotech assets under development. The company has issued statements explaining its accumulated deficit, emphasizing distinctions between cash and non-cash expenses, and describing its cost-disciplined operating approach.
Readers will also find regulatory and listing-related updates, such as Nasdaq notices regarding minimum bid price requirements, along with community and corporate responsibility stories, including charitable donations of personal holdings of Tevogen common stock by company leadership to local and international organizations. For those tracking the evolution of precision T cell therapy, AI-driven target discovery, and Tevogen’s sustainability-focused biopharma model, the TVGN news page provides an ongoing view of scientific, financial, and corporate developments.
Tevogen (Nasdaq: TVGN) signed a non-exclusive, non-binding Letter of Intent dated March 5, 2026 to evaluate a potential acquisition of Apozeal Pharmaceutical. The deal could provide Tevogen Generics with an established platform including 11 FDA-approved ANDA products, multiple ANDAs pending, and additional generics in development.
The transaction is subject to due diligence, negotiation of definitive agreements, regulatory approvals, and customary closing conditions, and there is no assurance the acquisition will be completed.
Tevogen (Nasdaq: TVGN) announced a 50-for-1 reverse stock split to regain compliance with Nasdaq's $1.00 minimum bid requirement. The split is expected to be effective at 12:01 a.m. on March 6, 2026, with shares trading on a split-adjusted basis under the same symbol and a new CUSIP.
No fractional shares will be issued; holders entitled to fractions will receive cash in lieu. Equity awards, warrants, incentive plan shares and preferred conversions will be proportionally adjusted. The company said the split will not affect underlying operations or total stockholders' equity.
Tevogen (Nasdaq: TVGN) announced a signed, non-exclusive, non-binding Letter of Intent dated Feb 27, 2026 to evaluate a potential acquisition of a global Contract Research Organization (CRO).
If completed, the transaction could expand clinical development capabilities, add revenue-generating services, and support a more capital-efficient growth model while remaining subject to due diligence and definitive agreements.
Tevogen (Nasdaq: TVGN) signed a non-exclusive, non-binding Letter of Intent on Feb 26, 2026 to evaluate a potential transaction to acquire a majority voting interest in Sciometrix and its Clinicus digital care management platform.
The deal would aim to make Tevogen a revenue-generating healthcare enterprise by integrating Clinicus' remote patient monitoring and predictive analytics with Tevogen.AI to support commercialization, value-based care, and optimized clinical trials; the transaction is subject to due diligence, definitive documentation, approvals and customary closing conditions.
Tevogen (Nasdaq: TVGN) signed a non-exclusive, non-binding Letter of Intent on Feb. 26, 2026 to evaluate a potential transaction to acquire a majority voting interest in Sciometrix and its Clinicus digital care management platform.
The deal, if completed, would aim to make Tevogen a revenue-generating healthcare enterprise by integrating Clinicus and remote patient monitoring with Tevogen.AI to accelerate commercialization readiness and enhance data, analytics, and value-based care capabilities. The proposal remains subject to due diligence, definitive agreements, approvals, and customary closing conditions.
Tevogen (NASDAQ: TVGN) said its Board will evaluate a potential one-time special cash dividend to shareholders, contingent on future financial milestones such as revenue and earnings targets. Any dividend would depend on future performance, capital needs, solvency law compliance, and final Board approval; timing and amount remain uncertain.
Tevogen (Nasdaq: TVGN) updated its long-term stock-based incentive program to tie awards to defined company milestones, explicitly including revenue. The modified plan applies to all eligible employees, officers, directors and consultants.
The company said it aims to pursue revenue generation in 2026 and to launch at least four blockbuster products by 2030, while expanding into scalable healthcare AI and potential asset acquisitions and joint ventures.
Tevogen (Nasdaq: TVGN) reported 2025 scientific and operational milestones focused on scaling its ExacTcell™ T cell platform, expanding cytotoxic T lymphocyte (CTL) programs across viral and oncology indications, and advancing in-house GMP cell therapy manufacturing readiness. 2025 achievements include improved lab yields per product, T cell target identification for five additional HLA restrictions for SARS-CoV-2 CTLs, and target discovery work for EBV, chronic hepatitis B, and HPV-related cancers supported by Tevogen.AI.
Management highlighted platform scalability, pipeline breadth, manufacturing foundation, and plans to discuss AI, financial strategy, and commercialization at J.P. Morgan.
Tevogen (Nasdaq: TVGN) announced on December 22, 2025 that Founder and CEO Dr. Ryan Saadi donated 230,000 shares of Tevogen common stock to SRLC USA, a United Nations-recognized 501(c)(3) nonprofit serving underserved communities.
The company said the transfer was conducted in accordance with SEC Rule 144 and that Dr. Saadi will not receive any proceeds from any disposal of the securities. The donation is described as supporting education initiatives for underprivileged children.
Tevogen (Nasdaq: TVGN) Founder and CEO Dr. Ryan Saadi donated 50,000 shares of his personal Tevogen common stock to the Mt. Bethel Fire Company to support emergency readiness in Warren Township on December 19, 2025. The contributed shares are intended to enhance safety, equipment and response capabilities.
The donation was executed under SEC Rule 144, and Dr. Saadi will not receive proceeds from any disposal of the securities. The announcement also states an estimated $10 billion asset valuation for the company and a secured cash runway through commercialization.